GlassScriptPhysician profile
Monique Blanchard
NPI 1649277047
$6,409.32
in general payments reported to CMS, 2019-2025
25 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,433 · 2022: $1,482 · 2023: $1,041 · 2024: $1,173 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,097 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,097.19 |
| Education | $397.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $901.44 | 2021-2025 | |
| Janssen Biotech, INC. | $620.76 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $614.39 | 2021-2025 | |
| Amgen INC. | $497.11 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $459.75 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $441.55 | 2021-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $439.37 | 2021-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $412.09 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $266.02 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $244.99 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $218.13 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $199.27 | 2021-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $194.98 | 2023-2025 | |
| Pfizer INC. | $189.81 | 2021-2025 | |
| Incyte Corporation | $162.84 | 2021-2025 | Opzelura |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $146.39 | 2021-2024 | |
| Galderma Laboratories, L.P. | $99.41 | 2021-2025 | Aklief |
| Almirall LLC | $88.43 | 2021-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $61.31 | 2024 | Vtama |
| Hill Dermaceuticals, INC. | $47.62 | 2022 | |
| Sandoz INC. | $39.86 | 2023 | Hyrimoz |
| Dermira, INC. | $20.98 | 2021 | |
| Biofrontera INC. | $17.93 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $15.31 | 2022 | |
| Organon LLC | $9.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Blanchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.